Literature DB >> 28926349

A Nurse-Led Care Program for Breast Cancer Patients in a Chemotherapy Day Center: A Randomized Controlled Trial.

Xiao Bin Lai1, Shirley Siu Yin Ching, Frances Kam Yuet Wong, Carenx Wai Yee Leung, Lai Ha Lee, Jessica Shuk Yin Wong, Yim Fan Lo.   

Abstract

BACKGROUND: Healthcare providers are facing the challenge of helping cancer patients cope with the impact of outpatient-based chemotherapy. A nurse-led care program was proposed to address this challenge.
OBJECTIVE: The aim of this study was to examine the effects of a nurse-led care program for patients receiving outpatient-based chemotherapy.
METHODS: This was a single-center, open-label, 2-arm parallel trial with equal randomization (NCT02228200). Breast cancer patients in Hong Kong were randomly allocated to the intervention arm or the control arm. The control arm received routine hospital care. The intervention arm received the nurse-led care plus the routine hospital care. The quality of life, self-efficacy, symptom distress levels, and satisfaction with care were evaluated with questionnaires before randomization (T0), in the middle of chemotherapy (T1), and 1 month after chemotherapy (T2). Individual interviews were conducted with some participants in the intervention arm at T2.
RESULTS: The intervention arm participants reported significantly lower distress levels from oral problems, fatigue, peripheral neuropathy, distressful feelings, and higher satisfaction with care. According to the satisfaction evaluation and the interviews, the participants stated that the service was helpful in providing information and communication opportunities, filling the service gap after drug administration, providing psychological support, relieving discomfort, and building confidence.
CONCLUSION: Breast cancer patients received support from the provision of comprehensive, continuous, and individualized care. IMPLICATIONS FOR PRACTICE: The nurse-led care program could be applied to breast cancer patients in other hospitals in Hong Kong. Exploring its applicability to cancer settings in other countries is recommended.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 28926349     DOI: 10.1097/NCC.0000000000000539

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  5 in total

Review 1.  Prevention and Management of Chemotherapy-Induced Polyneuropathy.

Authors:  Berit Jordan; Franziska Jahn; Sandra Sauer; Karin Jordan
Journal:  Breast Care (Basel)       Date:  2019-04-10       Impact factor: 2.860

2.  Follow-up after breast cancer: Variations, best practices, and opportunities for improvement according to health care professionals.

Authors:  Jet W Ankersmid; Jolanda C van Hoeve; Luc J A Strobbe; Yvonne E A van Riet; Cornelia F van Uden-Kraan; Sabine Siesling; Constance H C Drossaert
Journal:  Eur J Cancer Care (Engl)       Date:  2021-08-27       Impact factor: 2.328

3.  Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme).

Authors:  Elise Deluche; Tiffany Darbas; Kevin Bourcier; Loic Montangon; Geraldine Bayard; Evelyne Caille; Julie Querrioux; Chantal Suchaud; Sonia Zabaleta; Sabine Chaput; Valerie Le Brun-Ly; Julia Pestre; Laurence Venat; Frédéric Thuillier; Elodie Nevado; Gaelle Maillan; Jeremy Jost; Sophie Leobon; Nicole Tubiana-Mathieu; Sandrine Lavau-Denes
Journal:  Med Oncol       Date:  2020-07-25       Impact factor: 3.064

Review 4.  Nurse-led telehealth interventions for symptom management in patients with cancer receiving systemic or radiation therapy: a systematic review and meta-analysis.

Authors:  Chanel Kwok; Charlena Degen; Narges Moradi; Dawn Stacey
Journal:  Support Care Cancer       Date:  2022-04-14       Impact factor: 3.359

5.  A Nurse-Led mHealth Self-Management Program (mChemotherapy) for Breast Cancer Patients Undergoing Chemotherapy: Study Protocol of a Randomized Controlled Pilot Study.

Authors:  Nuo Shi; Arkers K C Wong; Frances K Y Wong; Nan Zhang; Xiaobin Lai; Lu Gan
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.